Hence, larger cohorts are required in order to validate the association of HER2 codon 655 AG and/or HER2 codon 655 GG polymorphisms with cardiotoxicity induced by trastuzumab-directed therapies in breast cancer patients. Here, ERBB2 is linked to breast carcinoma.